News

YAZ registered in Europe

Visual inspection: The new contraceptive YAZ® is soon to be launched in Europe.

Zoom image

Visual inspection: The new contraceptive YAZ® is soon to be launched in Europe.

Berlin – The new low-dose oral contraceptive YAZ® will soon be available on the European market, too. Bayer Schering Pharma recently received the necessary marketing authorization. The product is scheduled for launch in all major European markets in the fall of 2008.

YAZ® will be the first oral contraceptive on the European market containing the unique progestin drospirenone combined with a low dose of ethinyl estradiol in a new dosing regimen of 24 days of active hormone tablets and four days of placebo.

YAZ® has been available since April 2006 in the United States, where it is the only oral contraceptive ever approved for three distinct indications: contraception, treatment of moderate acne as well as treatment of the emotional and physical symptoms associated with pmdd (premenstrual dysphoric disorder), such as mood swings, irritability, anxiety, food cravings, breast tenderness, bloating and headache. Bayer Schering Pharma also plans to submit YAZ® for registration in Europe in the acne and pmdd indications.